Her2 targeted therapy drugs

targeted therapy options. The complete HER2-targeted therapies, potentially expanding the use of drugs like trastuzumab deruxtecan.

HER2-targeted therapies and HER2-positive breast cancer. HER2-positive breast cancers have a lot of a protein called HER2 on the surface of their cells. The HER2 protein is an important driver of cell growth and survival. HER2-targeted therapies are designed to treat HER2-positive breast cancers.

Anti-HER2 therapies (also called HER2 inhibitors or HER2-targeted therapies) are a class of medicines used to treat all stages of HER2-positive breast cancer and certain HER2-low breast cancers.

The following targeted therapy drugs are used to treat HER2-positive breast cancer. Trastuzumab Trastuzumab (Herceptin and biosimilars ) is the most common targeted therapy drug used to treat HER2-positive breast cancer.

HER2 positive cancer Trastuzumab. Trastuzumab is a targeted therapy drug used to treat HER2 positive secondary breast cancer. Pertuzumab. Pertuzumab is another targeted therapy drug that attaches to the HER2 protein (receptor). Phesgo Trastuzumab emtansine. Trastuzumab deruxtecan. Tucatinib.

HER2-positive tumors. All breast cancers are tested for HER2 status to help guide treatment. If a tumor is HER2-positive, the HER2-targeted therapy drug trastuzumab (Herceptin) is included in the chemotherapy regimen. Sometimes other drugs that target HER2 are used.

Anti-HER2 therapies (also called HER2 inhibitors or HER2-targeted therapies) are a class of medicines used to treat all stages of HER2-positive breast cancer.

Novel antibody drug conjugates and bispecific antibodies targeting HER2, and HER2-targeted therapies in combination with immune-checkpoint inhibition are all under investigation in clinical trials.

Breast cancers that are HER2-positive have large numbers of HER2 receptors on the surface of the cancer. The HER2 targeted therapies block these